Reported results
- Mitapivat (PYRUKYND and AQVESME) delivered worldwide net revenues of $55.4 million in the third quarter of 2026.
- U.S. net revenue for mitapivat was $48.7 million and ex-U.S. net revenue was $6.6 million in the third quarter of 2026.
- Research and Development (R&D) expenses were $73.5 million for the third quarter of 2026.
- Selling, General and Administrative (SG&A) expenses were $56.5 million for the third quarter of 2026.
- Cash, cash equivalents, and marketable securities were $907.0 million as of September 30, 2026.
Guidance
- Agios is targeting non-GAAP profitability in 2028.
Price and volatility reaction
The stock moved -9.9% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved +0.5 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 31.38 | 2026-11-04 |
| Close after release | 28.27 | 2026-11-05 |
| Realised move | -9.9% | close to close |
| 30d ATM IV change | +0.5 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.
